Information Provided By:
Fly News Breaks for January 10, 2020
Jan 10, 2020 | 09:14 EDT
Stifel analyst Annabel Samimy maintain Horizon Therapeutics (HZNP) as a Select List and Top Pick, citing the visible growth drivers of Krystexxa and teprotumumab as well as the company's "proven execution prowess." She also called Evolus (EOLS) an "underappreciated Select List Pick" given its "excellent execution" in the cash pay neurotoxin market. Among development-stage companies, Samimy selected Cara Therapeutics (CARA) as her Top Pick, noting that it will have three clinical trial read-outs in distinct pruritus indications this year and has lost nearly all value related to Oral Korsuva despite the drug's established clinical activity. She has Buy rating and $45 price target on Horizon, Buy rating and $33 price target on Evolus and Buy rating and $33 price target on Cara shares.
News For CARA;HZNP;EOLS From the Last 2 Days
There are no results for your query CARA;HZNP;EOLS